Pfizer Says Vaccine Trial Shows “Robust” Response In Kids 5 To 11
Monday September 20, Pfizer announced its COVID-19 trials in children ages 5 to 11 years age is showing "robust" results. This is certainly remarkable news and the approval for children to be vaccinated, couldn't come faster for most parents. According to CNN the highly anticipated news, came by way of the phase 2/3 trials and revealed the Covid-19 vaccine was safe and that it generated a "robust" antibody response in children in this age group.
This scientific trial used Pfizer's 2-dose regimen, over the course of 21 days and included 2,268 children ages 5 to 11 The dose for persons 12 and up is 30-micrograms, and the trial used a 10-microgram dose. The results were right on target and means hundreds of thousands of kids will soon have the opportunity to get their coronavirus shots.
Pfizer says they plan to submit the new data to the US Food and Drug Administration for emergency use authorization. Once that happens, FDA officials said that they will make the authorization in a matter of weeks for children ages 5 to 11 to be vaccinated.
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trial used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.